Effect of corticosteroid therapy on the progression of IgA nephropathy with moderate proteinuria

Clinical and Experimental Nephrology

Volumn 7, Issue 3, 2003, Pages 210-214

  Uzu, Takashi ^a   Harada, Tamaki ^a   Ko, Mie ^a   Yamato, Masafumi ^a   Takahara, Ken ^a   Yamauchi, Atsushi ^a  

^a OSAKA ROSAI HOSPITAL   (Japan)

Author keywords

IgA nephropathy; Moderate proteinuria; Repeated biopsy; Steroid

Indexed keywords

CORTICOSTEROID; CREATININE; PROTEIN; STEROID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; KIDNEY FUNCTION; MALE; MESANGIUM CELL; PROTEIN URINE LEVEL; PROTEINURIA; SURVIVAL RATE;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; BIOPSY; DISEASE PROGRESSION; FEMALE; GLOMERULONEPHRITIS, IGA; HUMANS; MALE; MIDDLE AGED; PROTEINURIA; TREATMENT OUTCOME;

EID: 0141891964     PISSN: 13421751     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10157-003-0236-0     Document Type: Article

References (24)

1. Velo M, Lozano L, Egido J, Gutierrez-Millet V, Hernando L. Natural history of IgA nephropathy in patients followed-up for more than 10 years in Spain. Semin Nephrol 1987;7:346-50.
2. Droz D, Kramar A, Nawar T, Noel LH. Primary IgA nephropathy: prognostic factors. Contrib Nephrol 1984;40:202-7.
3. Beukhof J, Kardaun O, Schaafsma W, Poortema K, Donker AJ, Hoedemaeker PJ, et al. Toward individual prognosis of IgA nephropathy. Kidney Int 1986;29:549-56.
4. Chauveau D, Droz D. Follow-up evaluation of the first patients with IgA nephropathy described at Necker Hospital. Contrib Nephrol 1993;104:1-5.
5. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 2000; 347:738-48.
6. Nolin L, Courteau M. Management of IgA nephropathy: evidence-based recommendations. Kidney Int 1999;Suppl 70:S56-S62.
7. Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 1999;353:883-7.
8. Shoji T, Nakanishi I, Suzuki A, Hayashi T, Togawa M, Okada N, et al. Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy. Am J Kidney Dis 2000;35:194-201.
9. Donadio JVJ, Grande JP, Bergstralh EJ, Dart RA, Larson TS, Spencer DC. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. J Am Soc Nephrol 1999;10:1772-7.
10. Levy M, Berger J. Worldwide perspective of IgA nephropathy. Am J Kidney Dis 1988;12:340-7.
11. Radford MGJ, Donadio JVJ, Bergstralh EJ, Grande JP. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 1997;8:199-207.
12. Alamartine E, Sabatier JC, Guerin C, Berliet JM, Berthoux F. Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses. Am J Kidney Dis 1991;18:12-19.
13. To KF, Choi PC, Szeto CC, Li PK, Tang NL, Leung CB, et al. Outcome of IgA nephropathy in adults graded by chronic histological lesions. Am J Kidney Dis 2000;35:392-400.
14. Koyama A, Igarashi M, Kobayashi M. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis 1997; 29:526-32.
15. Johnston P, Brown JS, Braumholtz DA, Davison AM. Clinico-pathological correlations and long-term follow-up of 253 United Kingdom patients with IgA nephropathy. A report from the MRC Glomerulonephritis Registry. Q J Med 1992;84:619-27.
16. Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M, et al. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. J Am Soc Nephrol 1999; 10:101-9.
17. Lai KN, Lai FM, Ho CP, Chan KW. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin Nephrol 1986;26:174-80.
18. Kobayashi Y, Fujii K, Hiki Y, Tateno S, Kurokawa A, Kamiyama M. Steroid therapy in IgA nephropathy: a retrospective study in heavy proteinuric cases. Nephron 1988;48:12-17.
19. Hotta O, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis 2001;38:736-43.
20. Locatelli F, Pozzi C, Del Vecchio L, Bolasco PG, Fogazzi GB, Andrulli S, et al. Role of proteinuria reduction in the progression of IgA nephropathy. Ren Fail 2001;23:495-505.
21. Waldo FB, Wyatt RJ, Kelly DR, Herrera GA, Benfield MR, Kohaut EC. Treatment of IgA nephropathy in children: efficacy of alternate-day oral prednisone. Pediatr Nephrol 1993;7:529-32.
22. Tateno S, Kobayashi Y. Quantitative analysis of mesangial areas in serial biopsied patients with IgA nephropathy. Nephron 1987; 46:28-33.
23. Locatelli F, Del Vecchio L, Pozzi C. The patient with IgA glomerulonephritis - what is the role of steroid treatment? Nephrol Dial Transplant 1999;14:1057-60.
24. Nieuwhof C, Kruytzer M, Frederiks P, van Breda Vriesman PJ. Chronicity index and mesangial IgG deposition are risk factors for hypertension and renal failure in early IgA nephropathy. Am J Kidney Dis 1998;31:962-70.